查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018818

泌尿生殖系统药物市场：2026-2032年全球市场预测（依适应症、治疗分类、给药途径、剂型、销售模式、通路和最终用户划分）

Genitourinary Drugs Market by Indication, Therapeutic Class, Route Of Administration, Formulation, Sales Model, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，泌尿生殖系统药物市场价值将达到 415.4 亿美元，到 2026 年将成长至 433.3 亿美元，到 2032 年将达到 558.8 亿美元，复合年增长率为 4.32%。

主要市场统计数据
基准年 2025 415.4亿美元
预计年份：2026年 433.3亿美元
预测年份 2032 558.8亿美元
复合年增长率 (%) 4.32%

全面概述了影响泌尿生殖系统治疗及其取得的人口统计、临床、监管和技术因素。

泌尿生殖系统治疗领域正经历着一场由人口结构、临床和技术因素共同驱动的动态变革。随着已开发国家人口老化，良性前列腺增生和膀胱过动症疾病的盛行率不断上升，同时，医疗保健模式转移的转变和患者期望的不断变化，也促使人们对兼具疗效和耐受性的药物提出了更高的要求。同时，药理学和药物递送技术的进步，拓展了口服、注射和外用等多种给药途径，为临床医生提供了更多个人化治疗的手段。

泌尿生殖健康服务提供方式的重新定义，在研发、商业化和供应韧性方面的结构性转变进行了详细的考察。

泌尿生殖系统药物市场正经历一场变革性的转变，不仅体现在新产品的分阶段上市，也体现在研发、商业化和医疗服务模式的结构性变革。临床创新正透过联合治疗和新型作用机制拓展治疗边界，而药物科学则正在开发新的给药途径，以提高患者的依从性和耐受性。这些科学进步是由商业性模式的转变所驱动的，例如以数位化为先导的病人参与模式、线上药局的兴起，以及对真实世界证据的日益重视，以支撑提案的价值主张。

重点分析 2025 年关税变化将如何影响泌尿生殖系统药物整个价值链的采购、筹资策略和商业运作。

美国将于2025年实施关税，这为泌尿生殖系统药物的整个价值链带来了多重挑战，也促使企业采取相应的因应措施。对活性成分、辅料和特殊包装材料等生产投入的成本审查日益严格，迫使企业重新评估筹资策略。为此，一些製造商加快了供应商多元化进程，并探索区域采购方案以降低关税波动带来的风险。另一些製造商则加强了策略性库存管理和期货合约，以平衡整个生产週期的采购成本。

关键细分洞察揭示了适应症、治疗分类、分销管道和剂型选择如何影响获取、处方和商业化策略。

要了解泌尿生殖系统治疗领域临床和商业性机会的交会点，需要敏锐地意识到细分市场中的细微差别。从适应症来看，该领域涵盖良性前列腺增生、勃起功能障碍、间质性膀胱过动症炎、膀胱过动症和尿道感染，每种疾病都有其独特的病程、诊断路径和终点，这些都会影响治疗方法的选择和医疗保险报销。从治疗分类来看，该领域包括5α还原酶抑制剂、α受体阻断剂、抗胆碱能药物、β3促效剂、联合治疗和PDE5抑制剂，清楚地界定了既定的标准治疗方案和正在积极创新的领域。

关键区域洞察突显了北美、欧洲、中东和非洲以及亚太地区的人口、监管和分销差异如何影响获取和采用。

区域趋势对泌尿生殖系统市场的治疗重点、法规环境和分销模式有显着影响。在美洲，人口老化、大规模的基层医疗体系和健全的专业医疗网络推动了对慢性病管理策略的持续需求。同时，健保报销机制和处方药目录选择流程也日益凸显了清晰的价值证明和疗效数据的重要性。相较之下，欧洲、中东和非洲与区域支付方的谈判以及公共采购机制导致了不同的市场采纳路径，一些市场倾向于集中竞标，而另一些市场则优先考虑与临床指南保持一致。

对现有企业产品组合、专业创新者和伙伴关係关係如何推动差异化定位和商业化成功进行策略竞争分析。

泌尿生殖领域的竞争格局呈现出多元化的特点，既有成熟的大型製药企业公司，也有专注于特定适应症和新型製剂的灵活中型企业。大型成熟製药公司正利用其商业规模以及与医院和药房建立的稳固关係，拓展其在5α-还原酶抑制剂和α阻断剂传统治疗领域的产品组合。同时，专业公司和新参与企业则专注于差异化的作用机制、联合治疗以及改进的给药系统，以解决耐受性和依从性问题，并力求透过与医生合作以及产生针对性证据来创造价值。

为製药业领导者提供一系列切实可行的建议，以协调研发重点、供应链韧性和通路策略，从而加速产品推广。

致力于最大化临床影响和商业性回报的行业领导者应采取一系列切实可行的优先事项，将创新、可及性和营运韧性相结合。首先，应将研发重点放在已证实存在未满足需求的适应症上，并投资于能够提高患者依从性和耐受性的联合治疗和给药技术，从而加强与支付方和临床医生之间的价值对话。其次，应透过以下方式增强供应链韧性：实现原料药(API) 和组件来源多元化；尽可能建立区域生产能力；以及实施健全的可追溯性方案，以降低贸易中断带来的风险。

一种透明且可重复的调查方法，结合了与专家的直接互动、二手文献的整合以及基于情境的运行分析。

本研究采用高度透明且可重复的调查方法，整合一手和二手讯息，强调资讯来源的检验检验和专家核实。一手资讯包括对临床医生、支付方、经销商以及研发负责人进行的结构化访谈，以及旨在了解处方行为和分销管道偏好的匿名医疗专业人员问卷。二手资讯则利用同行评审文献、监管指导文件、临床试验註册数据和企业资讯披露，为临床概况、安全性考虑和製剂趋势提供背景信息。

本报告总结瞭如何整合创新、证据产生和供应链稳健性以确保患者获得治疗和商业性永续性的结论。

总之，泌尿生殖系统治疗市场正处于一个策略性十字路口，临床创新、不断发展的通路和营运韧性在此交汇，共同塑造其未来的发展方向。治疗分类、联合治疗和製剂技术的进步有望改善患者的治疗效果，但要实现这些目标，需要使循证医学的产生与支付方的期望相符，确保可靠的供应链，并构建能够适应日益数位化和多元化通路环境的商业模式。那些投资于利用真实世界数据并根据区域和通路的特定趋势调整打入市场策略相关人员，将更有能力将临床进展转化为永续的患者用药途径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：泌尿生殖系统药物市场：依适应症划分

  • 良性摄护腺增生
  • 勃起功能障碍
  • 间质性膀胱炎
  • 膀胱过动症
  • 尿道感染

第九章 泌尿生殖系统药物市场（依治疗类别划分）

  • 5α-还原酶抑制剂
  • α受体阻断剂
  • 抗胆碱能药物
  • β3促效剂
  • 联合治疗
  • PDE5抑制剂

第十章：泌尿生殖系统药物市场：依给药途径划分

  • 注射药物
  • 口服
  • 外用

第十一章：泌尿生殖系统药物市场（依剂型划分）

  • 胶囊
  • 注射药物
  • 口服液
  • 药片

第十二章：泌尿生殖系统药物的市场销售模式

  • 非处方药
    • 店面销售
    • 在线的
  • 处方笺

第十三章：泌尿生殖系统药物市场：依通路划分

  • 医院药房
    • 私立医院
    • 公立医院
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立经营药房

第十四章：泌尿生殖系统药物市场：依最终用户划分

  • 诊所
    • 全科诊所
    • 泌尿系统诊所
  • 居家医疗
  • 医院
    • 二级医疗机构
    • 专科诊所
    • 三级医疗机构

第十五章：泌尿生殖系统药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：泌尿生殖系统药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章：泌尿生殖系统药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 美国泌尿生殖系统药物市场

第十九章 中国泌尿生殖系统药物市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Melinta Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-ED54C46E88A6

The Genitourinary Drugs Market was valued at USD 41.54 billion in 2025 and is projected to grow to USD 43.33 billion in 2026, with a CAGR of 4.32%, reaching USD 55.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 41.54 billion
Estimated Year [2026] USD 43.33 billion
Forecast Year [2032] USD 55.88 billion
CAGR (%) 4.32%

A comprehensive introduction that defines the demographic, clinical, regulatory, and technological forces reshaping genitourinary therapeutics and access

The genitourinary therapeutics landscape is in the midst of a dynamic evolution driven by demographic, clinical, and technological forces. Aging populations in advanced economies have elevated the prevalence of conditions such as benign prostatic hyperplasia and overactive bladder, while shifting care paradigms and patient expectations have intensified demand for medicines that balance efficacy with tolerability. Parallel advances in pharmacology and drug delivery are expanding therapeutic choices across oral, injectable, and topical modalities, offering clinicians more ways to personalize care.

At the same time, the sector is adapting to broader healthcare transformations. Digital health tools and telemedicine are changing how patients access consultations and prescriptions, with online pharmacies complementing traditional retail and hospital distribution channels. Payers and providers are increasingly focused on real-world evidence and value-based outcomes, prompting manufacturers to demonstrate comparative effectiveness and to invest in long-term safety data. Regulatory pathways are also evolving, with heightened scrutiny on post-marketing surveillance and on the quality of active pharmaceutical ingredients sourced from complex global supply chains.

Taken together, these trends underscore a critical inflection point for stakeholders across the ecosystem. Manufacturers, distributors, clinicians, and policymakers must align innovation with operational resilience, ensuring that new therapies reach appropriate patient populations while navigating pricing pressures, regulatory complexity, and shifting channels to care.

An in-depth exploration of the structural transformations in development, commercialization, and supply resilience that are redefining genitourinary care delivery

The genitourinary drug landscape is experiencing transformative shifts that extend beyond incremental product launches to structural changes in development, commercialization, and care delivery. Clinical innovation is broadening therapeutic frontiers through combination therapies and novel mechanisms of action, while formulation science is enabling alternative routes of administration that enhance adherence and tolerability. These scientific advances are converging with commercial shifts: digital-first patient engagement, the rise of online pharmacies, and greater emphasis on real-world evidence to substantiate value propositions.

Simultaneously, consolidation among manufacturers and strategic partnerships between pharma and technology firms are altering competitive dynamics. Companies are investing in data capabilities to support outcomes-based contracting and to generate post-approval insights that resonate with payers. On the supply side, there is an increasing focus on supply chain resilience, with manufacturers diversifying API sources and reassessing dependence on single geographies. Moreover, regulatory evolution-emphasizing pharmacovigilance and manufacturing quality-has prompted more proactive lifecycle management for mature assets.

These shifts are not isolated; they interact to create new windows of opportunity. Stakeholders who integrate innovations in therapeutic design with agile commercial models and robust evidence generation will be best positioned to capture clinical and market advantages, while those that lag in adapting distribution strategies or supply chain resilience risk erosion of market access and margin.

A focused analysis of how 2025 tariff changes influenced sourcing, procurement strategies, and commercial operations across the genitourinary pharmaceutical value chain

The implementation of United States tariff measures in 2025 has introduced a layered set of challenges and adaptive responses across the genitourinary drug value chain. Manufacturing inputs such as active pharmaceutical ingredients, excipients, and specialized packaging have become subject to heightened cost scrutiny, prompting companies to reassess sourcing strategies. In response, some manufacturers accelerated supplier diversification and explored regional sourcing alternatives to mitigate exposure to tariff-driven volatility. Others amplified strategic inventory management and forward contracting to smooth procurement costs across production cycles.

These adjustments have also influenced commercial operations and pricing strategies. Contract negotiations with distributors and institutional buyers have increasingly factored in input-cost uncertainty, underscoring the importance of transparent supply agreements and contingency clauses. Hospital pharmacies and larger healthcare systems have prioritized multi-source procurement to preserve formulary stability, while retail and online channels have monitored margin compression that could affect stocking decisions for higher-cost specialty agents.

Regulatory and compliance burdens have grown in parallel, as manufacturers document origin of materials with greater granularity to comply with trade rules and to support risk assessments. Ultimately, the tariff environment has reinforced the strategic imperative for operational flexibility: companies that combined cost-control measures with targeted investments in local manufacturing capability and supply chain traceability were better positioned to sustain product availability and collaborator confidence during a period of trade-related disruption.

Key segmentation insights that reveal how indication, therapeutic class, distribution channels, and formulation choices shape access, prescribing, and commercialization strategies

Segmentation nuances are central to understanding where clinical and commercial opportunities intersect within genitourinary therapeutics. Based on Indication the landscape spans Benign Prostatic Hyperplasia, Erectile Dysfunction, Interstitial Cystitis, Overactive Bladder, and Urinary Tract Infection, each presenting distinct patient journeys, diagnostic pathways, and endpoints that influence therapeutic choice and reimbursement conversations. Based on Therapeutic Class the field includes 5 Alpha Reductase Inhibitors, Alpha Blockers, Anticholinergics, Beta3 Agonists, Combination Therapies, and Pde5 Inhibitors, delineating both legacy standards of care and areas of active innovation.

Channel strategies differ considerably when viewed through the lens of Distribution Channel where Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies play complementary roles; the Hospital Pharmacies segment is further differentiated by Private Hospitals and Public Hospitals, and the Retail Pharmacies segment is further split into Chain Pharmacies and Independent Pharmacies, creating varied procurement practices and purchasing power dynamics. End User segmentation identifies Clinics, Homecare, and Hospitals as primary delivery contexts, with Clinics further classified into General Practice Clinics and Urology Clinics and Hospitals further segmented into Secondary Care Centers, Specialty Clinics, and Tertiary Care Centers, which shape prescribing patterns and access to specialist therapeutics.

Therapeutic delivery and commercial formulation also matter: Route Of Administration is categorized into Injectable, Oral, and Topical options while Formulation distinctions include Capsules, Injectable Solutions, Oral Solutions, and Tablets, each with implications for adherence, cold-chain logistics, and patient preference. Finally, Sales Model considerations separate Over The Counter from Prescription distribution, with the Over The Counter channel further subdivided into In-Store and Online modalities, influencing marketing approaches, margin structures, and regulatory oversight. Collectively, these segmentation dimensions reveal where clinical differentiation, reimbursement strategy, and distribution optimization must align for successful product adoption.

Critical regional insights highlighting how demographic, regulatory, and distribution differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific shape access and adoption

Regional dynamics exert a powerful influence on therapeutic priorities, regulatory environments, and distribution models within the genitourinary market. In the Americas demographic aging, a large primary care base, and a robust specialty care network drive sustained demand for chronic-condition management strategies, while reimbursement structures and formulary processes heighten the importance of clear value demonstration and outcomes data. Conversely, regional payer negotiations and public procurement mechanisms in Europe, Middle East & Africa produce diverse adoption curves, with some markets favoring centralized tenders and others emphasizing clinical guideline alignment.

In the Asia-Pacific region growth in healthcare infrastructure, rising middle-class demand for improved quality of care, and expanding telehealth platforms are creating new access pathways. Across all regions, distribution channel evolution-particularly the scaling of online pharmacies-interacts with local regulatory regimes to reshape patient access and adherence patterns. Differences in clinical practice, diagnostic rates, and treatment-seeking behavior also alter the relative importance of specific indications; for example, cultural attitudes toward sexual health can influence care-seeking for erectile dysfunction, while screening and diagnostic capacity affect identification of overactive bladder.

Taken together, these geographic distinctions require tailored market entry and commercialization tactics. Manufacturers and distributors must adapt evidence generation, pricing strategies, and channel engagement to local policy frameworks and patient behaviors in order to achieve sustainable access and therapeutic uptake across diverse regional contexts.

Strategic competitive analysis of how incumbent portfolios, specialty innovators, and partnerships drive differentiated positioning and commercialization success

Competitive dynamics in the genitourinary space are defined by a mix of established pharmaceutical leaders, specialty biopharmaceutical firms, and agile mid-sized companies that focus on niche indications or novel formulations. Large incumbent manufacturers maintain portfolio breadth across legacy therapeutic classes such as 5 Alpha Reductase Inhibitors and Alpha Blockers, leveraging commercial scale and established relationships with hospital and retail pharmacies. Specialty firms and newer entrants concentrate on differentiated mechanisms, combination therapies, and improved delivery systems that address tolerability or adherence issues, seeking to carve out value through physician engagement and targeted evidence generation.

Partnerships and licensing deals are common strategies to accelerate market access and to complement core capabilities, particularly where development expertise in formulation or regional commercialization networks is required. Companies are also investing in lifecycle management-reformulations, fixed-dose combinations, and extended-release technologies-to sustain competitiveness as therapeutic standards evolve. Additionally, firms that have developed robust digital engagement tools and outcomes-tracking platforms are gaining an advantage in payer discussions, enabling more persuasive value narratives anchored in real-world performance.

Across the competitive landscape, success increasingly depends on the integration of clinical differentiation with pragmatic commercialization plans. Organizations that align R&D investments with clear clinical unmet needs, while executing disciplined supply chain and channel strategies, are positioned to capture clinical adoption and to maintain durable commercial performance.

A pragmatic set of high-impact recommendations for pharmaceutical leaders to align R&D focus, supply chain resilience, and channel strategies to accelerate adoption

Industry leaders seeking to maximize clinical impact and commercial returns should adopt a set of actionable priorities that align innovation, access, and operational resilience. First, target development efforts toward indications with demonstrable unmet needs and invest in combination therapies or delivery technologies that improve adherence and tolerability, thereby strengthening value conversations with payers and clinicians. Second, enhance supply chain resilience by diversifying API and component sourcing, building regional manufacturing capacity where feasible, and instituting robust traceability protocols to reduce exposure to trade-related disruptions.

Third, tailor commercialization to channel realities: integrate online pharmacy strategies with traditional hospital and retail engagement, and develop channel-specific service offerings for chain versus independent pharmacies. Fourth, deploy real-world evidence generation programs and digital tools to support outcomes-based contracting and to substantiate long-term benefits; these initiatives should be closely linked to pharmacovigilance and post-marketing surveillance. Fifth, pursue strategic partnerships to extend geographic reach and to complement internal capabilities in formulation science, regulatory navigation, or localized commercial execution.

Taken together, these recommendations form a pragmatic roadmap: align R&D priorities with payer and clinician evidence needs, fortify supply chains, and execute nuanced channel strategies to ensure that clinical innovation translates into accessible, sustainable therapeutics for patients.

Transparent and reproducible research methodology combining primary expert engagement, secondary literature synthesis, and scenario-based operational analysis

This research synthesizes primary and secondary intelligence using a transparent, reproducible methodology that emphasizes source triangulation and expert validation. Primary inputs included structured interviews with clinicians, payers, distributors, and R&D leaders, combined with anonymized practitioner surveys designed to capture prescribing behavior and channel preferences. Secondary inputs comprised peer-reviewed literature, regulatory guidance documents, clinical trial registries, and company disclosures to contextualize clinical profiles, safety considerations, and formulation trends.

Analytical methods integrated qualitative synthesis with systematic evidence mapping to identify thematic shifts and competitive positioning. Supply chain and tariff impact assessments were constructed using input-cost sensitivity analysis and scenario testing to evaluate potential operational responses without presenting specific market sizing. Rigorous review cycles involved subject-matter experts in clinical urology, pharmacoeconomics, and supply chain management to validate assumptions and to refine conclusions. Data limitations and regional heterogeneities are explicitly noted throughout the report, and methodological appendices document interview protocols, inclusion criteria for secondary sources, and the logical steps used to derive strategic insights.

This approach ensures that findings are grounded in multiple perspectives and that recommendations reflect both clinical realities and commercial constraints, enabling stakeholders to apply the analysis with confidence across planning horizons.

A conclusion synthesizing how innovation, evidence generation, and supply chain robustness must be integrated to secure patient access and commercial sustainability

In conclusion, the genitourinary therapeutics space stands at a strategic crossroads where clinical innovation, distribution evolution, and operational resilience converge to determine future trajectories. Advances in therapeutic classes, combination regimens, and formulation technologies promise improved patient outcomes, but realizing that promise depends on aligning evidence generation with payer expectations, securing reliable supply chains, and adapting commercial models to an increasingly digital and channel-diverse environment. Stakeholders who invest in real-world data capabilities and who tailor market entry strategies to regional and channel-specific dynamics will be best positioned to transform clinical advances into durable patient access.

Concurrent challenges-such as trade-related cost pressures, regulatory scrutiny around manufacturing quality, and shifting patient expectations-require proactive mitigation through diversified sourcing, enhanced traceability, and stronger post-marketing surveillance. Ultimately, the institutions that integrate scientific differentiation with disciplined operational execution and nuanced channel engagement will deliver the greatest clinical value while maintaining commercial viability. This synthesis provides a strategic compass for executives, clinicians, and investors seeking to navigate a rapidly evolving market and to prioritize investments that deliver measurable patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genitourinary Drugs Market, by Indication

  • 8.1. Benign Prostatic Hyperplasia
  • 8.2. Erectile Dysfunction
  • 8.3. Interstitial Cystitis
  • 8.4. Overactive Bladder
  • 8.5. Urinary Tract Infection

9. Genitourinary Drugs Market, by Therapeutic Class

  • 9.1. 5 Alpha Reductase Inhibitors
  • 9.2. Alpha Blockers
  • 9.3. Anticholinergics
  • 9.4. Beta3 Agonists
  • 9.5. Combination Therapies
  • 9.6. Pde5 Inhibitors

10. Genitourinary Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Genitourinary Drugs Market, by Formulation

  • 11.1. Capsules
  • 11.2. Injectable Solutions
  • 11.3. Oral Solutions
  • 11.4. Tablets

12. Genitourinary Drugs Market, by Sales Model

  • 12.1. Over The Counter
    • 12.1.1. In-Store
    • 12.1.2. Online
  • 12.2. Prescription

13. Genitourinary Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
    • 13.1.1. Private Hospitals
    • 13.1.2. Public Hospitals
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies
    • 13.3.1. Chain Pharmacies
    • 13.3.2. Independent Pharmacies

14. Genitourinary Drugs Market, by End User

  • 14.1. Clinics
    • 14.1.1. General Practice Clinics
    • 14.1.2. Urology Clinics
  • 14.2. Homecare
  • 14.3. Hospitals
    • 14.3.1. Secondary Care Centers
    • 14.3.2. Specialty Clinics
    • 14.3.3. Tertiary Care Centers

15. Genitourinary Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Genitourinary Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Genitourinary Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Genitourinary Drugs Market

19. China Genitourinary Drugs Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. AbbVie Inc.
  • 20.7. Amgen Inc.
  • 20.8. Astellas Pharma Inc.
  • 20.9. AstraZeneca plc
  • 20.10. Aurobindo Pharma Limited
  • 20.11. Bayer AG
  • 20.12. Boehringer Ingelheim International GmbH
  • 20.13. Bristol-Myers Squibb Company
  • 20.14. Cipla Limited
  • 20.15. Dr. Reddy's Laboratories Limited
  • 20.16. Eli Lilly and Company
  • 20.17. Endo International plc
  • 20.18. F. Hoffmann-La Roche AG
  • 20.19. Ferring International Center S.A.
  • 20.20. GlaxoSmithKline plc
  • 20.21. Hikma Pharmaceuticals PLC
  • 20.22. Johnson & Johnson Services, Inc.
  • 20.23. Melinta Therapeutics Inc.
  • 20.24. Merck & Co., Inc.
  • 20.25. Novartis AG
  • 20.26. Pfizer Inc.
  • 20.27. Sanofi S.A.
  • 20.28. Takeda Pharmaceutical Company Limited
  • 20.29. Teva Pharmaceutical Industries Ltd.
  • 20.30. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 246. GCC GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 249. GCC GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 250. GCC GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 251. GCC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 253. GCC GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. GCC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GCC GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. G7 GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 288. G7 GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 289. G7 GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 290. G7 GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. G7 GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 292. G7 GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 293. G7 GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. G7 GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 295. G7 GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. NATO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. NATO GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. NATO GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 301. NATO GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 302. NATO GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 303. NATO GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 304. NATO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 305. NATO GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 306. NATO GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. NATO GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 308. NATO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 309. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA GENITOURINARY DRUGS M